Safety of sitagliptin in treatment of hepatocellular carcinoma in chronic liver disease patients - Archive ouverte HAL Access content directly
Journal Articles Liver Cancer International Year : 2021

Safety of sitagliptin in treatment of hepatocellular carcinoma in chronic liver disease patients

(1, 2, 3) , (2) , (2) , (2) , (2) , (2) , (2) , (3, 4) , (3, 5) , (3, 5) , (2) , (2) , (1, 3) , (1, 2, 3)
1
2
3
4
5
Bruno Charbit
Darragh Duffy

Abstract

Background & Aims : Systemic therapies for hepatocellular carcinoma (HCC) treatment have limited efficacy and poor safety. Dipeptidyl peptidase-4 inhibitors were initially developed and approved as treatment for type 2 diabetes, yet oral administration of sitagliptin has recently been shown to improve naturally occurring tumour immunity in animal models of HCC. Methods : We conducted a phase Ib clinical trial to evaluate the impact of a pre-operative 3-week DPP4 inhibitor (sitagliptin) treatment in HCC patients undergoing liver resection. The primary objective was to evaluate the safety of a sitagliptin treatment in each of the three groups of patients, according to an escalating dosage of sitagliptin (100, 200 and 600 mg/d). Secondary objectives included the assessment of DPP4 activity, cytokine expression in plasma samples and circulating immune populations. Results : Fourteen patients were included and analysed. In all three dose groups, no severe adverse event related to sitagliptin was reported. A significant inhibition of DPP4 activity was observed upon sitagliptin treatment, which prevented the N-terminal truncation of CXCL10, leading to a mobilization of circulating CD8+ T cells and eosinophils. Immunochemistry analysis showed a lymphoid infiltration in all tumour samples with the presence of a population of CXCR3+ T cells in all but one of the tumours. Positivity for CXCL10 (IP10) and CCR3 in tumour and/or stroma cells was found in all resection pieces. Conclusion : In summary, sitagliptin can be used safely in patients with chronic liver disease and HCC, and could be tested in phase 2 trial, as an adjuvant in combination with others drugs, for the treatment of HCC patients.
Fichier principal
Vignette du fichier
Safety_of_sitagliptin_in_treatment_of_hepatocellul.pdf (1.27 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

pasteur-03384283 , version 1 (18-10-2021)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Clémence Hollande, Jeremy Boussier, Estelle Mottez, Vincent Bondet, Tan Phuc Buivan, et al.. Safety of sitagliptin in treatment of hepatocellular carcinoma in chronic liver disease patients. Liver Cancer International, 2021, pp.Online Version of Record before inclusion in an issue. ⟨10.1002/lci2.36⟩. ⟨pasteur-03384283⟩
10 View
40 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More